STOCK TITAN

T2 Biosystems Inc - TTOO STOCK NEWS

Welcome to our dedicated news page for T2 Biosystems (Ticker: TTOO), a resource for investors and traders seeking the latest updates and insights on T2 Biosystems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect T2 Biosystems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of T2 Biosystems's position in the market.

Rhea-AI Summary
T2 Biosystems, Inc. extends capital equipment supplier agreement with Vizient, Inc. through March 31, 2025, providing access to rapid sepsis detection products. The agreement reaffirms the value of T2 Biosystems' technology in improving patient outcomes and offers hospitals access to FDA-cleared diagnostic tools.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
-
Rhea-AI Summary
T2 Biosystems, Inc. (TTOO) plans to launch the T2Lyme Panel in Q3 2024, highlighting clinical benefits of T2Resistance Panel and engaging Dr. Robinson as a strategic advisor. The Company aims to regain Nasdaq compliance by May 2024 and expects 2024 revenue growth of 49% to 64%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.89%
Tags
none
-
Rhea-AI Summary
T2 Biosystems, Inc. (TTOO) announced a conference call to discuss T2Lyme Panel launch plans and business updates. The call will be held on March 20, 2024, at 8:30 a.m. Eastern Time. Investors can access the webcast at www.t2biosystems.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.2%
Tags
conferences
Rhea-AI Summary
T2 Biosystems, Inc. announced a new study showcasing the clinical benefits of the T2Resistance Panel, highlighting high accuracy, rapid detection times, and significant impact on clinical interventions. The study demonstrated 94.7% clinical sensitivity and 97.4% specificity, with results available in 4.4 hours compared to 58.3 hours for blood culture-based methods. The publication emphasized the importance of direct-from-blood detection of resistance genes for faster targeted therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.98%
Tags
none
-
Rhea-AI Summary
T2 Biosystems, Inc. (TTOO) secures continued listing on Nasdaq Stock Market after Nasdaq Hearings Panel grants extension for compliance with Market Value requirement. The Company aims to maintain liquidity, attract talent, access capital, and enhance merger opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.58%
Tags
none
-
Rhea-AI Summary
T2 Biosystems, Inc. reported record fourth quarter U.S. T2Bacteria Panel sales and achieved full year 2023 total revenue of $7.2 million. The Company executed contracts for 26 T2Dx Instruments in 2023 and expanded its international distribution network. Recent highlights include FDA clearances for new panels and a Phase 2 award. Financially, the Company presented a plan to regain compliance with Nasdaq listing requirements and amended its term loan agreement with CRG. Cash and cash equivalents stood at $15.7 million as of December 31, 2023. The Company expects significant revenue growth in 2024, focusing on sepsis and related product revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.71%
Tags
earnings
Rhea-AI Summary
T2 Biosystems, Inc. announces a definitive agreement to convert $15 million of its term loan into equity, strengthening its balance sheet. The company is working on important business catalysts like international distribution expansion and FDA clearances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.71%
Tags
none
-
Rhea-AI Summary
T2 Biosystems, Inc. (NASDAQ:TTOO) announced exclusive distribution agreements in the Netherlands, Belgium, Vietnam, and Switzerland to sell sepsis detection products. The agreements aim to expand international commercial business. The move targets high-prevalence regions for sepsis and antibiotic resistance, offering rapid detection solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.71%
Tags
none
-
Rhea-AI Summary
T2 Biosystems receives FDA clearance for expanded T2Bacteria Panel to detect Acinetobacter baumannii, a critical bloodstream infection pathogen. The addition enhances the panel's value proposition and covers 75% of sepsis-causing bacterial pathogens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.72%
Tags
clinical trial
Rhea-AI Summary
T2 Biosystems, Inc. (NASDAQ:TTOO) will report financial results for Q4 and full year 2023 and business updates on February 15, 2024. A conference call will be held at 4:30 p.m. ET. Investors can access the live webcast at www.t2biosystems.com or dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 106354.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences earnings
T2 Biosystems Inc

Nasdaq:TTOO

TTOO Rankings

TTOO Stock Data

14.80M
3.35M
7.55%
21.55%
5.99%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
US
Lexington

About TTOO

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www